Phase I study of weekly anti-insulin-like growth factor-I receptor (IGF-IR) monoclonal antibody IMC-A12 in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Cixutumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company; ImClone Systems
- 17 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 22 Sep 2010 Planned end date changed from 1 Sep 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 28 Oct 2009 Actual patient number (24) added as reported by ClinicalTrials.gov.